Ontvang nu dagelijks onze kooptips!

word abonnee
IEX 25 jaar desktop iconMarkt Monitor

Aandeel OpGen OTC:OPGN.Q, US68373L5057

Vertraagde koers (usd) Verschil Volume
1,960   0,000   (0,00%) Dagrange 0,000 - 0,000 0  

Curetis-OpGen - 2020: wordt het nog wat..?

2.575 Posts
Pagina: «« 1 ... 91 92 93 94 95 ... 129 »» | Laatste | Omlaag ↓
  1. forum rang 4 Pitmans 2 april 2020 09:40
    Ah, toch nog gevonden. Alleen het linkje is weggehaald, maar de url stond nog in m'n history.
    curetis.com/investors/

    Maatschappelijk kapitaal 55 miljoen stukken, waarvan 26 miljoen uitgegeven. Die 2 miljoen waren dus niet voor overname van de ongeplaatste stukken (neem aan dat die uberhaupt niet in de ruil zitten toch ?)

    Yorkville is nu wel uitgespeeld, zit er toch nog 1 positief punt aan de huidige situatie.
  2. forum rang 10 DeZwarteRidder 2 april 2020 09:47
    quote:

    Pitmans schreef op 2 april 2020 09:29:

    Curetis heeft per direct ook z'n IR-pagina van de site gehaald. Via het menuutje rechtsboven kun je nog wel naar IR, maar alleen die van opgen.

    Dat van die 2 miljoen stukken snap ik echt niet. Het zou de grap wel helemaal compleet maken.
    Die 2 miljoen stond waarschijnlijk in de kleine lettertjes.

    Amerikanen weten precies hoe je de tegenpartij voor de gek kunt houden.
  3. forum rang 4 Pitmans 2 april 2020 10:22
    quote:

    Pitmans schreef op 2 april 2020 09:40:

    Yorkville is nu wel uitgespeeld, zit er toch nog 1 positief punt aan de huidige situatie.
    Dat zeg ik wel, maar zou het hiermee te maken kunnen hebben ?
    www.sec.gov/Archives/edgar/data/12938...

    Lijkt erop dat er 500k stukken vande 2,6mljoen gereserveerd worden voor Yorkville.

    ==================================

    Item 1.01 Entry into a Material Definitive Agreement.

    As previously disclosed, on September 4, 2019, OpGen, Inc. (the “Company”) entered into a business combination transaction pursuant to an Implementation Agreement (the “Implementation Agreement”), by and among the Company, Curetis N.V., a public company with limited liability under the Laws of the Netherlands (“Curetis”), and Crystal GmbH, a private limited liability company organized under the laws of the Federal Republic of Germany and wholly owned subsidiary of the Company (the “Purchaser”). Under the Implementation Agreement, the Company agreed to assume, as a condition to closing the transactions under the Implementation Agreement, all of the outstanding convertible notes (the “Convertible Notes”) issued by Curetis in favor of YA II PN, LTD (“Yorkville”), pursuant to that certain Agreement for the Issuance of and Subscription to Notes Convertible into Shares and Share Subscription Warrants, dated October 2, 2018, by and between Curetis and Yorkville.

    On February 24, 2020, the Company entered into an Assignment of the Agreement for the Issuance of and Subscription to Notes Convertible into Shares (the “Assignment Agreement”) with Curetis and Yorkville. The Assignment Agreement satisfies the Company’s condition to closing of assuming the Convertible Notes and provides that, effective as of the closing of the transactions contemplated by the Implementation Agreement, the Company will assume all of the outstanding Convertible Notes. In addition, pursuant to the Assignment Agreement, upon assumption of the Convertible Notes by the Company, the Convertible Notes will cease to be convertible into shares of Curetis and will instead be convertible into shares of the Company’s common stock, par value $0.01. The Assignment Agreement provides that an amount of 500,000 shares of the Company’s common stock that comprise a portion of the consideration payable by the Company under the Implementation Agreement will be reserved for issuance under the Convertible Notes. The Company also agreed to register for resale up to 1,000,000 shares of Company common stock issuable upon conversion of the Convertible Notes within the later of 60 days following the later of the filing of the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 and the closing of the transactions contemplated by the Implementation Agreement.

    Each Convertible Note has a maturity of 12 months from its date of issuance. Curetis, or after closing of the transaction contemplated by the Implementation Agreement, the Company, has the right to extend such maturity by an additional 12-month period, while paying a cash fee equal to 5% of the principal amount of the relevant Convertible Notes. Subject to certain limitations, the maturity period can be extended up to four times.

    The Convertible Notes shall not accrue interest, except in the case of an event of default under the Convertible Notes, in which case the Convertible Notes shall accrue default interest at a rate of 15% per annum until the earlier of the date that the event of default is cured or the date on which the Convertible Notes have been fully converted or redeemed.

    The Convertible Notes may be converted at any time until they are fully redeemed. Upon conversion of one or more Convertible Notes into shares of the Company’s common stock, the number of Company shares will be calculated by dividing the aggregate principal amount of the relevant Convertible Notes by 93% of the lowest daily volume weighted average price of the Company common stock on the Nasdaq Capital Market over the 10 trading days prior to the conversion date.

    The Convertible Notes may be freely transferred, except to retail investors, and subject to compliance with applicable securities laws. The Convertible Notes contain anti-dilution protection, which protects the holder of the security from equity dilution resulting from later issues of shares at a lower price or value than that provided for in the security. The protection in the Convertible Notes takes the form of tying the conversion price of the Convertible Notes to the prevailing market price of the underlying shares of Company common stock so that changes to the share price due to share issuances, share splits or other potentially dilutive events will result in a corresponding change in the number of shares of Company common stock issuable upon conversion of a Convertible Note.

    As of February 24, 2020, an aggregate amount of €1.3 million of unconverted Convertible Notes was outstanding
    =======================================================

    En uit de gefilede stukken zelf :

    "Initial Conversions. As of the date of the Closing under the Implementation Agreement, five hundred thousand (500,000) of the shares of OpGen common stock (the “Initial Tranche OpGen Shares”) that comprise the Consideration under the Implementation Agreement shall be set aside and reserved for issuance to the Investor from time to time upon conversions by the Investor of portions of that amount of principal of the outstanding Notes using the same conversion terms under the Original Agreement, but substituting OpGen Shares for Curetis Shares (the “Initial Conversions”)."
  4. forum rang 10 DeZwarteRidder 2 april 2020 10:29
    quote:

    Pitmans schreef op 2 april 2020 10:22:

    [...]Dat zeg ik wel, maar zou het hiermee te maken kunnen hebben ?
    www.sec.gov/Archives/edgar/data/12938...

    Lijkt erop dat er 500k stukken vande 2,6mljoen gereserveerd worden voor Yorkville.
    ==================================

    Item 1.01 Entry into a Material Definitive Agreement.

    As previously disclosed, on September 4, 2019, OpGen, Inc. (the “Company”) entered into a business combination transaction pursuant to an Implementation Agreement (the “Implementation Agreement”), by and among the Company, Curetis N.V., a public company with limited liability under the Laws of the Netherlands (“Curetis”), and Crystal GmbH, a private limited liability company organized under the laws of the Federal Republic of Germany and wholly owned subsidiary of the Company (the “Purchaser”). Under the Implementation Agreement, the Company agreed to assume, as a condition to closing the transactions under the Implementation Agreement, all of the outstanding convertible notes (the “Convertible Notes”) issued by Curetis in favor of YA II PN, LTD (“Yorkville”), pursuant to that certain Agreement for the Issuance of and Subscription to Notes Convertible into Shares and Share Subscription Warrants, dated October 2, 2018, by and between Curetis and Yorkville.

    On February 24, 2020, the Company entered into an Assignment of the Agreement for the Issuance of and Subscription to Notes Convertible into Shares (the “Assignment Agreement”) with Curetis and Yorkville. The Assignment Agreement satisfies the Company’s condition to closing of assuming the Convertible Notes and provides that, effective as of the closing of the transactions contemplated by the Implementation Agreement, the Company will assume all of the outstanding Convertible Notes. In addition, pursuant to the Assignment Agreement, upon assumption of the Convertible Notes by the Company, the Convertible Notes will cease to be convertible into shares of Curetis and will instead be convertible into shares of the Company’s common stock, par value $0.01. The Assignment Agreement provides that an amount of 500,000 shares of the Company’s common stock that comprise a portion of the consideration payable by the Company under the Implementation Agreement will be reserved for issuance under the Convertible Notes. The Company also agreed to register for resale up to 1,000,000 shares of Company common stock issuable upon conversion of the Convertible Notes within the later of 60 days following the later of the filing of the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 and the closing of the transactions contemplated by the Implementation Agreement.

    Each Convertible Note has a maturity of 12 months from its date of issuance. Curetis, or after closing of the transaction contemplated by the Implementation Agreement, the Company, has the right to extend such maturity by an additional 12-month period, while paying a cash fee equal to 5% of the principal amount of the relevant Convertible Notes. Subject to certain limitations, the maturity period can be extended up to four times.

    The Convertible Notes shall not accrue interest, except in the case of an event of default under the Convertible Notes, in which case the Convertible Notes shall accrue default interest at a rate of 15% per annum until the earlier of the date that the event of default is cured or the date on which the Convertible Notes have been fully converted or redeemed.

    The Convertible Notes may be converted at any time until they are fully redeemed. Upon conversion of one or more Convertible Notes into shares of the Company’s common stock, the number of Company shares will be calculated by dividing the aggregate principal amount of the relevant Convertible Notes by 93% of the lowest daily volume weighted average price of the Company common stock on the Nasdaq Capital Market over the 10 trading days prior to the conversion date.

    The Convertible Notes may be freely transferred, except to retail investors, and subject to compliance with applicable securities laws. The Convertible Notes contain anti-dilution protection, which protects the holder of the security from equity dilution resulting from later issues of shares at a lower price or value than that provided for in the security. The protection in the Convertible Notes takes the form of tying the conversion price of the Convertible Notes to the prevailing market price of the underlying shares of Company common stock so that changes to the share price due to share issuances, share splits or other potentially dilutive events will result in a corresponding change in the number of shares of Company common stock issuable upon conversion of a Convertible Note.

    As of February 24, 2020, an aggregate amount of €1.3 million of unconverted Convertible Notes was outstanding
    =======================================================

    En uit de gefilede stukken zelf :

    "Initial Conversions. As of the date of the Closing under the Implementation Agreement, five hundred thousand (500,000) of the shares of OpGen common stock (the “Initial Tranche OpGen Shares”) that comprise the Consideration under the Implementation Agreement shall be set aside and reserved for issuance to the Investor from time to time upon conversions by the Investor of portions of that amount of principal of the outstanding Notes using the same conversion terms under the Original Agreement, but substituting OpGen Shares for Curetis Shares (the “Initial Conversions”)."
    Ik vermoed dat je gelijk hebt; dit maakt de overname wel heel erg (tragi)komisch.....!!!

    En van de resterende ca 2 miljoen aandelen kan nog eens 20% worden ingehouden om de kosten van de liquidatie te dekken.

    In dat geval zou er slechts ca 15 cent overblijven voor de Curetis-aandeelhouders.
2.575 Posts
Pagina: «« 1 ... 91 92 93 94 95 ... 129 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.